AQST
Aquestive Therapeutics, Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US
$3.83
+1.32%Oct 15, 2026, 11:00 UTC
The U.S. Food and Drug Administration accepted Aquestive Therapeutics’ resubmitted NDA for Anaphylm as complete and assigned a PDUFA goal date of March 16, 2027.
Source:Oct 14, 2026, 11:32 UTC
Aquestive Therapeutics agreed to serve as Eton Pharmaceuticals' exclusive manufacturer and supplier of the product under a supply agreement with an initial 20-year term.
Oct 14, 2026, 10:50 UTC
Eton Pharmaceuticals, Inc. and Aquestive Therapeutics, Inc. announced an exclusive U.S. licensing and supply agreement for LIBERVANT (diazepam) buccal film.
Source:Sep 29, 2026, 11:25 UTC
Aquestive Therapeutics, Inc. appointed Richard J. Daly as a director effective October 14, 2026, granting him 57,000 stock options under the company's 2018 Equity Incentive Plan.
Sep 17, 2026, 11:00 UTC
Aquestive Therapeutics resubmitted its New Drug Application to the U.S. Food and Drug Administration for Anaphylm (dibutepinephrine) sublingual film for the treatment of Type I allergic reactions, including anaphylaxis.
Source:Aug 11, 2026, 20:01 UTC
Aquestive Therapeutics reported its financial results for the second quarter ended June 30, 2026.
Aug 10, 2026, 11:00 UTC
Aquestive Therapeutics announced positive topline results from human factors and pharmacokinetic studies for its Anaphylm (dibutepinephrine) sublingual film, supporting a planned NDA resubmission to the FDA in Q3 2026.